Oncology

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.

Pharmacists play a vital role in precision oncology, enhancing treatment decisions for metastatic breast cancer through genetic testing and targeted therapies.

Oral SERDs and combination therapies are redefining post-CDK4/6 treatment in HR+/HER2– metastatic breast cancer.

Explore innovative supplemental screening options for breast cancer, enhancing access and accuracy for women with dense breasts and inconclusive mammograms.

Discover how innovative imaging detection methods, including MRI and proteomics, enhance breast cancer screening and support pharmacists in patient care.

Exploratory analysis shows 1 in 4 patients maintain a long-term response to ribociclib.

Explore the advancements and challenges of allogeneic CAR T-cell therapies, including immune rejection and innovative engineering strategies for cancer treatment.

Multidisciplinary approaches are crucial in treating complex cancer patients, focusing on tailored therapies and symptom management strategies.

Pharmacists play a crucial role in optimizing CAR-T therapy outcomes by guiding bridging therapy decisions and enhancing patient safety through proactive collaboration.

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in patients with multiple myeloma.

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

Project Optimus transforms cancer treatment by optimizing dosing strategies, enhancing efficacy, and reducing toxicities in modern therapies.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

Although highly efficacious, patient selection and adverse event management are crucial.

Discover how the combination of palbociclib, trastuzumab, and endocrine therapy enhances survival in HER2-positive advanced breast cancer patients.

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

Pirtobrutinib’s indication was expanded for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, allowing for treatment in earlier lines of therapy.